Molecular identification and classification have been instrumental in aiding clinical management decisions and targeted therapy selections in recent years. With respect to the ever-rising incidence of clinically detected thyroid nodules, The Cancer Genome Atlas (TCGA) has characterized the genetic alterations of approximately 90% of papillary thyroid carcinomas (PTCs), thus filling in several gaps in the identification of driver mutations in thyroid cancer. 1 Until the early 2000s, genetic alterations in thyroid carcinoma were poorly understood and identified in merely 20% of cases. Beginning in the 2000s when the BRAF-V600E mutation was identified in approximately 45% of PTCs, the clinical utility of thyroid molecular profiling became apparent with the prognostic information associated with a BRAF-V600E mutation. 2 Over the past decade, data on the indolent nature of the encapsulated follicular variant of papillary thyroid carcinoma (EFVPTC) have accumulated, particularly with respect to the noninvasive subset. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Additional studies have also begun to reveal that these noninvasive EFVPTC nodules have shown more "indolent" molecular profiles as well. 6, 9, 11, 13, 14 Due to the overwhelming outcome data as well as molecular evidence that has come to light, the Endocrine Pathology Society working group proposed a nomenclature revision of the entity "noninvasive EFVPTC" to "noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)," removing the term carcinoma, or malignant implication, from the name. 9 Since then, there have been approximately 15 studies published illustrating the prevalence of particular molecular changes in NIFTP nodules. 9, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Our study aimed to examine our own cohort of NIFTP cases at our large academic institution where molecular data are used in clinical decision making for thyroid nodules, allowing our data to contribute to the limited existing literature regarding this new entity. Benign and malignant thyroid nodules are managed differently. While malignant thyroid nodules often necessitate a total thyroidectomy with radioactive iodine ablation (RAI) and intensive follow-up, this prolonged treatment regimen is not only unnecessary for benign neoplasms and neoplasms of low malignant potential but also harmful. Side effects of overly extensive surgery or unnecessary use of RAI, psychosocial stress of a cancer diagnosis, and increased health care expenditures both initially and throughout the years of follow-up [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] 29 are all hazards of overtreatment of nodules that can otherwise be successfully managed with lobectomy alone. NIFTP is one such low-risk tumor where the most appropriate treatment is lobectomy rather than total thyroidectomy and RAI. To assist in presurgical identification of NIFTP, we and others have previously described cytomorphologic 13, 25, [30] [31] [32] [33] [34] [35] and sonographic [36] [37] [38] [39] characteristics of NIFTP. NIFTP nodules display microfollicular architecture with PTC-like nuclear features on cytology 25, 30, 32, 34, 35 and smooth nodule borders and lack of microcalcifications on ultrasound. 36, 37 In the current study, we analyze the molecular findings of fine-needle aspiration (FNA) specimens of surgically confirmed NIFTP nodules to determine whether molecular alterations associated with NIFTP can further assist in clinical management decisions.
Materials and Methods
The current study protocol was approved by the New York University Cancer Institute Protocol Review and Monitoring Committee and by the New York University Institutional Review Board.
A search was conducted in our laboratory information system for thyroid surgical pathology resections of noninvasive EFVPTC/NIFTP (henceforth, this category will be referred to as NIFTP), with Afirma gene-expression classifier (GEC) (Veracyte, South San Francisco, CA) and/ or ThyroSeq v2 using targeted next-generation sequencing (NGS) (University of Pittsburgh Medical Center, Pittsburgh, PA) testing from January 2013 through May 2017. Cases lacking a preceding in-house FNA of the same nodule (as determined by correlation between radiologic findings, biopsy site, and location in the surgical specimen) and cases lacking sufficient material for molecular testing were excluded. For any patient with multiple FNAs of the same nodule, only the most recent FNA specimen was included. All EFVPTC and NIFTP surgical pathology cases considered for the current study were reviewed by two pathologists (T.C.B. and C.Z.L.), and cases demonstrating any vascular or capsular invasion (including minimal invasion) or any true papillae were excluded from the study. Cases in which the entire capsule was not submitted or the surgical pathology slides were unable to be retrieved for review were also excluded. One case that met the original NIFTP criteria was excluded due to the presence of a solid component (<30%) because the entire tumor parenchyma of this case was not submitted at the time of specimen sampling and the molecular profile included a TERT mutation. Presurgical FNA reports of 39 surgically confirmed NIFTP cases from January 2013 through May 2017 were assessed for Afirma/ThyroSeq results.
Ultrasound-guided thyroid FNA was performed by radiologists, endocrinologists, or cytopathologists with 23-gauge to 27-gauge needles. All molecular specimens were collected according to manufacturer specifications in Afirma GEC and/or ThyroSeq vials. Cases diagnosed as The Bethesda System (TBS) category III-atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) or TBS category IV-follicular neoplasm/suspicious for follicular neoplasm (FN) were sent for molecular testing. Occasionally, TBS category II-benign or TBS category V-suspicious for malignancy cases were sent for molecular testing if the patient had either a prior AUS/FLUS or FN diagnosis, or an outside consult diagnosis of AUS/FLUS or FN. The choice of Afirma GEC vs ThyroSeq v2 testing was at the discretion of the ordering clinician. While Afirma GEC was the initially the predominantly requested test, more recently, ThyroSeq v2 has become the standard molecular test.
Results
Thirty-nine cases of surgically confirmed NIFTP had molecular testing during the study period ❚Figure 1❚. The mean patient age was 47.3 years with a female predominance (67%). Mean nodule size was 2.59 cm. Twenty patients had lobectomy, while the remaining 19 patients had a total thyroidectomy ❚Table 1❚. TBS diagnoses were as follows: TBS II in one case, TBS III in 23 cases, TBS IV in 12 cases, and TBS V in three cases. Twenty-seven nodules were preoperatively tested with ThyroSeq (nine of which had both Afirma and Thyroseq testing): 18 (67%) cases had RAS mutations (13 NRAS, four HRAS, one KRAS) ❚Image 1❚ and ❚Image 2❚; three of the 18 had multiple alterations (NRAS and TP53, n = 1; NRAS and PTEN, n = 2). One additional case with two mutations showed BRAF T599_R603 and EIF1AX mutations (n = 1). Other isolated molecular changes included PTEN mutation (n = 1), MET overexpression (n = 1), PAX8/PPARG fusion (n = 3), and THADA/IGF2BP3 fusion (n = 3). Twenty-one cases had Afirma testing: 19 cases were Afirma suspicious, and two cases were Afirma benign. One of the two Afirma-tested benign nodules also had a ThyroSeq test result showing both NRAS + PTEN mutations. Of note, all but one (NRAS + TP53) of the dual-alteration cases received a total thyroidectomy rather than lobectomy.
Discussion
Follicular patterned lesions of the thyroid have typically been shown to have RAS or RAS-like mutations, particularly in encapsulated or well-demarcated nodules; these lesions most commonly lack BRAF-V600E and other aggressive BRAF-V600E-like mutations (typically associated with classical PTC). 6, 9, 11, 13, 14, 40 In this study, NIFTP tumors demonstrated a distinct molecular profile associated with histologically follicular neoplasms. Our study supports and adds to the evolving data on this newly defined entity. In our cohort, all but two cases with Afirma testing demonstrated a "suspicious" Afirma result, and all cases with ThyroSeq testing demonstrated molecular alterations. These findings support the notion that NIFTP is still a neoplastic entity despite its indolent behavior. While Afirma provides a binary result rather than a specific genetic alteration, this information can still aid in identifying NIFTP, as NIFTP cases were most often Afirma suspicious illustrating that a clonal alteration was present. When examining the particular ThyroSeq alterations, similar to other studies, most (67%) of the cases demonstrated RAS mutations, with 72% of those being NRAS mutations. No cases demonstrated BRAF-V600E mutations.
Most of the literature examining the molecular profile of NIFTP nodules, like our own study, has found that NIFTP nodules generally lack BRAF-V600E mutations (or "BRAF-like" mutations) and display more indolent "RAS-like" mutations. 9, 15, 16, 20, [25] [26] [27] Curiously, a few Korean studies have found that small percentages of NIFTP cases have in fact displayed BRAF-V600E mutations. 18, 19, 21 However, it is possible that a complete examination of the parenchyma would have excluded an NIFTP diagnosis in these cohorts. 21 In the current study, we observed one case that fit the criteria for NIFTP as outlined by the Endocrine Pathology Society working group 9 that had to be excluded due to the combination of a few factors. First, this case contained multiple alterations, one of which was a TERT mutation, which has been associated with a more aggressive tumor course in many cases. Second, this case ❚Figure 1❚ Breakdown of cases with noninvasive follicular thyroid neoplasm with papillary-like nuclear features, Bethesda categories, and molecular results. displayed several areas with solid growth (<30%). Due to the large size of this tumor, the entire tumor parenchyma was not submitted at the time of specimen sampling, and therefore a confident assessment of the percentage of solid growth could not be made. The newly updated NIFTP criteria imply that cases with TERT mutations may be excluded from a diagnosis of NIFTP. 41 TCGA performed a comprehensive and multiplatform molecular classification of 496 PTC cases. Using an unsupervised clustering method, two meta clusters were identified: BRAF-V600E-like and RAS-like mutation tumors. Of note, the tumors in the RAS-like cluster were highly differentiated and displayed follicular variant of PTC (FVPTC) histology and low recurrence rates, with distinct messenger RNA (mRNA) and microRNA expression profiles, and occurred in younger patients. 1 With the introduction of NIFTP, several groups 9,15-28 explored its molecular characterization, which, prior to the nomenclature change, fell into the FVPTC category of the TCGA and other studies ❚Table 2❚.
The criteria for the diagnosis of NIFTP, as outlined by the Endocrine Pathology Society working group, rely on the examination of several parenchymal attributes within the tumor capsule: the tumor must display less than 1% papillae, lack psammoma bodies, display less than a 30% solid/trabecular/insular growth pattern, lack high mitotic activity, and lack tumor necrosis. 9 The recently updated NIFTP criteria exclude cases with any papillae (even <1%) and cases with florid PTC nuclear features (achieving 3/3), with a recommendation to examine the entire tumor parenchyma in such cases. 41 Therefore, it would be difficult to achieve a confident diagnosis of NIFTP without an assessment of the entire parenchyma. In situations where the entire tumor parenchyma is not ❚Image 2❚ Case of noninvasive follicular thyroid neoplasm with papillary-like nuclear features with an HRAS mutation (A) is well circumscribed, without a defined capsule (H&E, ×200; inset ×100). B, The nuclei show enlargement, elongation, focal overlapping, small nucleoli, chromatin clearing, chromatin margination, chromatin glassiness, and membrane irregularity (H&E, ×600).
❚Image 1❚ Case of noninvasive follicular thyroid neoplasm with papillary-like nuclear features with an NRAS mutation (A) is a well-circumscribed, partially encapsulated nodule, with a focus of cellular crowding and microfollicles in the left half of the image (H&E, ×200) . B, The nuclei show enlargement, elongation, overlapping, small nucleoli, chromatin clearing, chromatin margination, and membrane irregularities (H&E, ×400).
examined, molecular analysis can serve as a diagnostic supplement to aid in clinical decision making in cases suspected to be NIFTP.
In our institution, our policy for gross examination of thyroid nodules is to submit the entire tumor when the size is 4 cm or less. Of note, NIFTP tumors 4 cm or larger have been shown to lead an indolent course, similar to their smaller counterparts. 42, 43 In evaluation of tumors larger than 4 cm, our practice is to submit the entire capsule with up to 50% tumor parenchymal sampling. As also mentioned by other authors, it may not be practical to assess the entire tumor parenchyma of all NIFTP nodules. 18 According to the strict criteria for NIFTP, the diagnosis should only be made when the entire parenchyma is examined. However, in practice, cases lacking capsular and vascular invasion and meeting the NIFTP criteria on the examined tissue have been called NIFTP when the entire tumor capsule was sampled, even if the entire parenchyma was not submitted. Therefore, an examination into the tumors' molecular profile is crucial.
In addition, molecular assessment is useful for cases that fall out of the NIFTP category due to parenchymal features (ie, >30% solid growth pattern or presence of psammomatous calcification), especially in cases with heterogeneous architectural and nuclear patterns. This particularly applies when tumors become difficult to categorize because they fall short of a PTC or even an infiltrative FVPTC diagnosis but also do not fit into the NIFTP category.
Based on the overwhelming consensus of the existing literature on molecular profiling of NIFTP nodules displaying that NIFTP nodules predominantly have RAS-like mutations and lack BRAF-V600E-like mutations, 9, 15, 16, 20, [25] [26] [27] it stands to reason that cases with RASlike mutations can continue to be treated as tumors with low malignant potential even without complete examination of the tumor parenchyma (whether or not they can be termed NIFTP or must fall into another low malignant potential category is still a question). The molecular profiling of tumor nodules would also serve as a complement to histologic diagnoses in terms of BRAF-V600E-like mutations, pointing toward the possibility of invasion or classical PTC in cases lacking invasion upon initial histologic sectioning. BRAF-V600E-like mutations may be a hint toward the presence of more aggressive histologic features that should potentially be sought out with additional tumor sectioning and/or examination of deeper levels of the histologic tumor blocks. It is possible, even for those who may disagree with calling RAS-like mutations NIFTP unless the entire parenchyma confirms the NIFTP diagnosis, that a diagnosis of NIFTP should be excluded in cases with an aggressive or BRAF-V600E-like mutation as implied in the recently updated NIFTP criteria. 41 Tumor nodules with BRAF-V600E-like mutations have been shown to have a more aggressive nature, which may be explained by more aggressive histologic features potentially present but just unobserved due to incomplete tumor sampling or a lack of exhaustively sectioning entire tumor blocks. In addition, not every case of NIFTP or invasive EFVPTC is straightforward, even upon expert evaluation. Therefore, a certain level of interobserver variability must be considered. As elucidation of thyroid molecular alterations becomes more advanced with modern technologies, it seems that the time to start incorporating molecular profiles into the tumor diagnosis is now. NIFTP nodules with BRAF-V600E-like mutations should potentially be excluded from an NIFTP diagnosis altogether because there are likely features present but just unobserved (or undercalled, in the case of interobserver variability), which portend a more aggressive course, or the tumorigenesis of a nodule with such an alteration is more likely to become more aggressive in the near future.
In summary, tumors that would achieve the greatest benefit from molecular characterization include cases that fit the strict NIFTP criteria but lack an examination of the entire tumor parenchyma, as well as noninvasive encapsulated lesions that are excluded from an NIFTP diagnosis secondary to parenchymal features but do not necessarily fit well into another category (ie, cases with a single psammoma body or with 40% solid component not meeting solid variant of PTC criteria). In addition, cases with unfavorable molecular alterations (ie, BRAF-V600E-like mutations and potentially also including NIFTP cases with a more "malignant" expression profile, as illustrated in an mRNA expression analysis by Giannini et al 15 ) may need to be excluded from the NIFTP category or at minimum should warrant continued extensive sampling and search for potentially invasive tumor foci.
In conclusion, our study displays that NIFTP cases tend to show molecular alterations, with most cases displaying RAS mutations. Our findings add to the limited existing literature on NIFTP. Because patient management decisions are not based on only one feature (be it clinical, cytologic, sonographic, or molecular), our group has previously examined cytologic 30 and sonographic 36 presurgical attributes of NIFTP and, in the current study, elucidated the molecular profiles of NIFTP found at our large academic institution. Armed with all of these comprehensive data points, clinicians and surgeons may now proceed to make more educated and efficient decisions for patient management. Our group plans to continue to explore molecular profiling of thyroid tumors and hope to follow up with an ❚Table 2❚ (cont)
